Drugs / JX11502MA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05233657 | Jan 2020 → Jan 2022 | schizophrenia | Zhejiang Jingxin Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06356389 | Mar → Dec 2022 | schizophrenia | Zhejiang Jingxin Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JX11502MA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05233657 ↗ |
| Action | Activate | “JX11502MA is a potent partial agonist of dopamine D2 and D3 receptors” PMID 38054696 ↗ Feb 2024 |
| Route | Oral | “Participants received JX11502MA capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once” NCT05233657 ↗ |